Why the study?
Does combination therapy with candesartan and spironolactone cause severe hyperkalemia in patients with hypertensive nephrosclerosis and mildly decreased renal function?
Does combination therapy with candesartan and spironolactone cause severe hyperkalemia in patients with hypertensive nephrosclerosis and mildly decreased renal function?
Combination therapy with ARBs and spironolactone requires strict monitoring of serum potassium to prevent life-threatening hyperkalemia, especially in patients with decreased renal function.
Answers are grounded in this paper and cite their sources.
Severe hyperkalemia risk persists with ARB-spironolactone despite mild renal impairment; case report leaves open incidence and monitoring needs in broader cohorts.
We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function. Recently, ARBs are replacing the ACE inhibitors. The combined therapy with ARB and spironolactone will eventually become the standard regimen. The strict attention and close monitoring of serum potassium should be mandatory in combination therapy to prevent hyperkalemia. Assessment of trans-tubular potassium gradient (TTKG) and fractional excretion of potassium (FEK) before starting the therapy would help in identifying the patients at higher risk of developing hyperkalemia. Co-administration of thiazide or loop diuretics is recommended to reduce the risk of hyperkalemia.
No takes yet. Share an insight, caveat, or question.
Fujii et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: